Platelet Inhibition to Target Reperfusion Injury

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 228 participants.

Also called NCT03102723

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 228 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03102723
Other papers using this trial's data
  • Effect of Cangrelor on Infarct Size in ST-Segment-Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention: A Randomized Controlled Trial (The PITRI Trial) Circulation, 2024-07-09 DOI, PubMed 38742915, PMC11224569 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Singapore (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03102723. Randomized; quadruple masking; primary purpose treatment. Start 2017-10-01 (actual); primary completion 2022-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Platelet Inhibition to Target Reperfusion Injury
Acronym
PITRI
Condition
STEMI
Intervention (Drug)
Cangrelor
Lead sponsor
National Heart Centre Singapore (class: other)
Collaborator
Tan Tock Seng Hospital (class: other)
Collaborator
National University Hospital, Singapore (class: other)
Collaborator
Khoo Teck Puat Hospital (class: other)
Collaborator
Changi General Hospital (class: other)
Collaborator
Sengkang General Hospital (class: other)

Record details

Record id
cardio:ct-nct03102723
Content hash
33356794cf2bec3cbf10656bce1b3fe0721f7d9f96d8b553f6de359e69f05c33